Concentration-Controlled Everolimus (Certican): Combination with Reduced Dose Calcineurin Inhibitors
Author:
- 1 May 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (Supplement) , S76-S79
Abstract
The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their association with dose-related nephrotoxicity is a major factor in the development of chronic allograft nephropathy in kidney transplant recipients. The novel proliferation signal inhibitor everolimus (Certican) has a mode of action distinct and complementary to the CNIs, which is thought to underlie the demonstrated synergy between everolimus and cyclosporine (CsA) in preclinical models. This finding suggests that everolimus may allow for CNI dose reduction, enabling nephrotoxicity to be minimized without compromising efficacy. Two prospective, multicenter, randomized studies have investigated the efficacy and safety of everolimus (1.5 or 3.0 mg/day) combined with reduced-exposure CsA (Neoral) in de novo renal transplant patients. In these studies, the everolimus trough level was maintained at ≥3 ng/ml with therapeutic drug monitoring and the CsA dose optimized with C2 monitoring. The incidence of efficacy failure with this regimen was shown to be comparable with that provided by regimens employing full-dose CNIs, but with good renal function. Furthermore, everolimus (trough levels 3–8 ng/ml) plus reduced-exposure CsA was associated with a marked reduction in acute rejection compared with regimens using fixed-dose everolimus or mycophenolate mofetil plus full-dose CsA. At 12 months follow-up, CsA trough level was 57% lower in these trials than in previous trials in which patients received full-dose CsA. This suggests that concentration-controlled everolimus can be successfully combined with optimized administration of CsA and that this regimen may maximize immunosuppression, whilst preserving renal function.Keywords
This publication has 14 references indexed in Scilit:
- Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label StudyTransplantation, 2004
- Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol HistologyTransplantation, 2004
- Long-Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?American Journal of Transplantation, 2004
- The impact of donor age on the results of renal transplantationNephrology Dialysis Transplantation, 2004
- Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6-Month Safety and Efficacy Results of Two Randomized StudiesAmerican Journal of Transplantation, 2004
- Post-transplant renal function in the first year predicts long-term kidney transplant survivalKidney International, 2002
- Long-term kidney transplant survivalAmerican Journal of Kidney Diseases, 2001
- Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathyKidney International, 2001
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997